J&J Exploring Procrit Neuroprotective Indication: Anemia Drug To CNS Arena?
Executive Summary
Johnson & Johnson is exploring a neuroprotective indication for its anemia therapy Procrit (epoetin alfa), Senior VP-Global Development Robert Wills, PhD, told analysts during J&J's R&D day May 30 in La Jolla, Calif.